In the case of BRCAness tumors (found in breast, prostate, pancreatic, or ovarian cancer), most germline BRCA1/2 mutants are biallelically inactivated, indicating their sensitivity to PARP inhibitors. The gene discussed is BRCA1; the disease is ovarian carcinoma.